

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)



(10) International Publication Number
WO 2023/118545 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/7088 (2006.01)

(21) International Application Number:
PCT/EP2022/087670

(22) International Filing Date:
23 December 2022 (23.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21217418.9 23 December 2021 (23.12.2021) EP

(71) Applicant: SECARNA PHARMACEUTICALS GMBH
& CO. KG [DE/DE]; Bismarckstr. 7, 35037 Marburg (DE).

(72) Inventors: DE LOS REYES, Marta Lucia; Theresien-
str. 114, 80333 München (DE). JASCHINSKI, Frank; c/o
Bismarckstr. 7, 35037 Marburg (DE). MICHEL, Sven; c/
o Bismarckstr. 7, 35037 Marburg (DE). URI, Anna; Euck-
enstr. 1B, 81369 München (DE).

(74) Agent: WITMANS, H.a., V.O., P.O. Box 87930, 2508 DH
Den Haag (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NLRP3 OLIGONUCLEOTIDE FOR USE IN PREVENTING AND/OR TREATING AN INFLAMMATORY DISEASE

(57) Abstract: The present invention refers to oligonucleotide consisting of 12 to 20 nucleotides comprising at least one modified nucleotide hybridizing with a nucleic acid sequence of NLR family pyrin domain containing 3 (NLRP3) and a pharmaceutical composition 5 comprising such oligonucleotide together with a pharmaceutically acceptable carrier, excipient and/or dilutant to inhibit the expression of NLRP3 for example for preventing and/or treating an inflammatory disease.



WO 2023/118545 A1